Summary
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth.
By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population.
Enquire About Report: http://www.radiantinsights.com/research/pharmapoint-migraine-global-drug-forecast-and-market-analysis-to-2023
Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Highlights
Key Questions Answered
- The migraine market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market?
Will the drugs under development fulfil the unmet needs of the migraine market?
- The late-stage migraine pipeline is filled with therapies with diverse formulations and routes of administration. Which drug will have a significant impact on the migraine market. Which of these drugs will have the highest CAGR, and why?
- The migraine market is currently dominated by generic drugs. How will the introduction of combinations of device and drugs, and new classes of therapies change the treatment landscape once reimbursement is not a problem anymore?
How will the drug treatment rates change over the next ten years?
What are the key drivers and barriers to this change?
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth.
By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population.
Enquire About Report: http://www.radiantinsights.com/research/pharmapoint-migraine-global-drug-forecast-and-market-analysis-to-2023
Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile.
Highlights
Key Questions Answered
- The migraine market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market?
Will the drugs under development fulfil the unmet needs of the migraine market?
- The late-stage migraine pipeline is filled with therapies with diverse formulations and routes of administration. Which drug will have a significant impact on the migraine market. Which of these drugs will have the highest CAGR, and why?
- The migraine market is currently dominated by generic drugs. How will the introduction of combinations of device and drugs, and new classes of therapies change the treatment landscape once reimbursement is not a problem anymore?
How will the drug treatment rates change over the next ten years?
What are the key drivers and barriers to this change?
About Us
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
For More Information Visit – Radiant Insights
Contact:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Email: sales@radiantinsights.com
No comments:
Post a Comment